MAIA Biotechnology, Inc. (MAIA)
NYSEAMERICAN: MAIA · Real-Time Price · USD
1.820
-0.100 (-5.21%)
At close: May 13, 2025, 4:00 PM
1.790
-0.030 (-1.65%)
Pre-market: May 14, 2025, 8:27 AM EDT
MAIA Biotechnology Employees
MAIA Biotechnology had 13 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
13
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,515,728
Market Cap
53.85M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 13 | 0 | - |
| Dec 31, 2023 | 13 | -5 | -27.78% |
| Dec 31, 2022 | 18 | 9 | 100.00% |
| Dec 31, 2021 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MAIA News
- 8 days ago - CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement - Business Wire
- 8 days ago - MAIA Biotechnology Announces $1.08 Million Private Placement - Business Wire
- 6 weeks ago - MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders - Business Wire
- 7 weeks ago - MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025 - Business Wire
- 7 weeks ago - MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug - Business Wire
- 7 weeks ago - MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO - Business Wire
- 2 months ago - MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients - Business Wire
- 2 months ago - MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer - Business Wire